

Utilizing Valid, Reliable, and Practical Measures of Health Status in Primary Geriatric Care: Translating Research into Usual Care The Senior's Health Assessment Report and Plan (SHARP<sup>™</sup>) Ted Rosenberg MD MSc FRCPC<sup>1</sup>



University Of British Columbia and HomeTeam Medical Services™, Victoria BC Canada

## **Summary: The SHARP**<sup>™</sup>

- The Senior's Health Assessment Report and Plan (SHARP<sup>™</sup>) is a 60minute assessment done by a nurse.
- Compared to most medical diagnoses, components of the SHARP<sup>™</sup> were stronger predictors of:
  - Death.
  - Nursing home transfer.
  - Hospital admission.
- The SHARP<sup>™</sup> is performed:

## Patient Care - Case Study

86-year-old woman, falling, depressed, with recurrent ER visits. SHARP<sup>™</sup> results: CFS 6, Gait Speed 0.62 m/s, Grip Strength 10.0 kg, and GDS-5 4/5.

Meet with patient to review risks for nursing home transfer and hospital admission using patient education tool graphs (see bottom left).

"I don't like exercise. but I do not want to go to a nursing home or the hospital"

- ) At baseline, when patients first enter the practice.
- 2) Annually.
- <u>Components</u> of the SHARP<sup>™</sup> are also repeated:
  - 1) To evaluate interdisciplinary team interventions.
  - 2) When health status changes.
- The SHARP<sup>™</sup> is reviewed with patients and their family caregivers to:
  - Develop a care plan.
  - Develop individualized goals of care.
  - Motivate patients for treatment.
- The SHARP<sup>™</sup> is also shared with case managers, homecare nurses, congregate care facilities, and hospitals.
- Aggregated SHARP<sup>™</sup> results are used to define population needs and for program planning and evaluation.

# The Components of the SHARP $^{\scriptscriptstyle\rm M}$

- Clinical Frailty Scale (CFS)
- EuroQOL EQ-5D-5L for Health-Related Quality of Life
- EuroQOL EQ-VAS Visual Analog Scale for General Health
- Gait Speed (over 3m)

**MD/RN:** Change amitriptyline to escitalopram, discontinue zopiclone, fine tune treatment for congestive heart failure, inject steroid and prescribe topical diclofenac for knee osteoarthritis.

**PT/Rehab Aide:** Therapy for knee and supervised exercise plus independent home exercise program.

8-week reassessment: Gait speed 0.78m/s, GDS-5 1/5. Continue rehabilitation.

12-week reassessment: No change in outcome measures. Discontinue regular rehab visits, continue independent home exercise program, and change to monthly monitoring visits.

1-year reassessment: No ER visits, moved to independent retirement home for greater social support.

## **Program Planning and Evaluation**

### **Changing Population Needs**

Example: Using SHARP<sup>™</sup> data to measure changes in our population averages for <u>new</u> patients entering the practice over time.

Year 1

Year 3

**Practice Mean (Intake)** 

- Grip Strength
- Montreal Cognitive Assessment (MoCA)
- Geriatric Depression Scale (GDS-5 question version)
- Months of the Year Backwards (MYB)
- Mini Nutritional Assessment<sup>®</sup> (MNA-6)
- 3 oz. Water Swallow Test (WST)

### **Sample Patient Education Tool<sup>2</sup>**



Gait Speed (m/s)	0.68	0.50
MoCA	22	20
GDS-5	1.5	2.0
MNA-6	11	9
% of patients with CFS of 6	58	76

**Possible Interpretation:** New patients to the practice seem to be increasingly physically and mentally frail.

**Planning Considerations:** What other needs do our patients have? Should we add an Occupational Therapist and/or Dietician to our interdisciplinary team? Do we need to increase allocation for rehabilitation aides? Consider closer tracking/support for caregiver stress. Consider closely tracking hypnotic/sedative drug use to lower fall risk. Consider increasing interventions for osteoporosis.

### **Evaluation of Effectiveness of Team Interventions**

Example: Measuring changes from baseline risk measures for <u>current</u> patients after 1 year.

<b>Practice Mean</b>	Intake	1 year	Interpretation
Gait Speed (m/s)	0.68	0.79	Improved and maintaining gains.
MoCA	22	20	Expected cognitive decline, consider other cognitive interventions.
GDS-5	2.4	1.0	Improvement in mood.
EQ-5D	0.73	0.86	Improvement in quality of life.
EQ-VAS	68	82	Improvement in self-reported health.
MNA-6	10	10	No change in nutritional risk. Needs review.
% of patients with CFS of 6	58	72	Mix of higher risk new patients and aging. (Note – CFS does not usually improve in frail individuals)

<sup>2</sup>Outcomes data based on HomeTeam Medical Services<sup>™</sup> practice population. Results published in BMJ Open 2019. <u>https://bmjopen.bmj.com/content/9/11/e032712.info</u>

### Conclusion

**Standardized testing with the SHARP**<sup>TM</sup>:

- Is acceptable to patients.
- Is efficient.
- Supports individual patient care by an interdisciplinary team.
- Supports data aggregation and program planning and evaluation.

### **Acknowledgements**

Vikki Hay, Kelly Townsend, Kris Yue, Laura Stewart, Stefanie Renn, Rory Lattimer, and Liza Zacharias.

<sup>1</sup>Corresponding Author: Ted Rosenberg, MD <u>trosenberg@hometeammedical.ca</u>